EQ Equillium

Equillium to Participate in Upcoming Investor Conferences

Equillium to Participate in Upcoming Investor Conferences

LA JOLLA, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- , Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced that management will participate in the following upcoming investor conferences:

Stifel Healthcare Conference
Format:Company Presentation & 1x1 Meetings
Date:Wednesday, November 12, 2025
Time:3:20-3:50 PM EDT



Jefferies Global Healthcare Conference in London
Format:1x1 Meetings
Date:Tuesday, November 18 – Thursday, November 20, 2025



Members of the Equillium management team will be available to participate in meetings with investors who are registered to attend the conference.

Investors and the general public are invited to listen to a live webcast of the presentation on the page, located under the Investor Relations section on . An archived replay of both presentations will be available for 90 days.

About Equillium

Equillium is a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need. The company’s pipeline consists of several novel immunomodulatory assets and product platform targeting immuno-inflammatory pathways. 

For more information, visit .

Investor Contact

PJ Kelleher

LifeSci Advisors, LLC





EN
04/11/2025

Underlying

EQEquillium

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Equillium

 PRESS RELEASE
Free
EQ EQUILLIUM

Equillium to Participate in the Leerink Partners 2026 Global Healthcar...

Equillium to Participate in the Leerink Partners 2026 Global Healthcare Conference LA JOLLA, Calif., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today announced that management will participate in a fireside chat at the Leerink Partners 2026 Global Healthcare Conference on Wednesday, March 11, 2026 at 10:40am ET. Members of the Equillium management team will be available to participate in meetings with investors who are registered to attend the conference. Abou...

February 25, 2026 1 EN
 PRESS RELEASE
Free
EQ EQUILLIUM

Equillium Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(...

Equillium Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) LA JOLLA, Calif., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today announced that on January 30, 2026, the Compensation Committee of Equillium’s Board of Directors granted inducement awards consisting of nonstatutory stock options to purchase an aggregate of 59,750 shares of common stock to two new employees under Equillium’s 2024 Inducement Plan. The Compensation Committee approved the sto...

February 2, 2026 1 EN
 PRESS RELEASE
Free
EQ EQUILLIUM

Equillium to Participate in Upcoming Investor Conferences

Equillium to Participate in Upcoming Investor Conferences LA JOLLA, Calif., Nov. 20, 2025 (GLOBE NEWSWIRE) -- , Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced that management will participate in the following upcoming investor conferences: Piper Sandler 37th Annual Healthcare ConferenceFormat:Fireside Chat & 1x1 MeetingsDate:Tuesday, December 2, 2025Time:11:30 AM EST Evercore ISI 8th Annual Healthcare ConferenceFormat:Fireside Ch...

November 20, 2025 1 EN
 PRESS RELEASE
Free
EQ EQUILLIUM

Equillium Reports Third Quarter 2025 Financial Results and Provides Op...

Equillium Reports Third Quarter 2025 Financial Results and Provides Operational Update Closed financing of up to $50 million; initial tranche of $30 million provides runway through 2027 Hosted key opinion leader event highlighting the important role of the Aryl Hydrocarbon Receptor (AhR) in intestinal inflammation, the unmet medical need in ulcerative colitis, and the potential clinical utility of EQ504, a novel oral AhR modulator EQ504 Phase 1 clinical study initiation planned for mid-2026 LA JOLLA, Calif., Nov. 13, 2025 (GLOBE NEWSWIRE) -- , Inc. (Nasdaq: EQ), a clinical-stage biotec...

November 13, 2025 1 EN
 PRESS RELEASE
Free
EQ EQUILLIUM

Equillium to Participate in Upcoming Investor Conferences

Equillium to Participate in Upcoming Investor Conferences LA JOLLA, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- , Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced that management will participate in the following upcoming investor conferences: Stifel Healthcare Conference Format:Company Presentation & 1x1 MeetingsDate:Wednesday, November 12, 2025Time:3:20-3:50 PM EDT Jefferies Global Healthcare Conference in LondonFormat:1x1 Meetings...

November 4, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch